| # | Title | Journal | Year | Citations |
|---|
| 1 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Blood | 2016 | 5,965 |
| 2 | Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia | Blood | 2013 | 313 |
| 3 | A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy | Blood | 2018 | 130 |
| 4 | Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study | Lancet Oncology, The | 2019 | 101 |
| 5 | Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy | European Journal of Cancer | 2001 | 90 |
| 6 | Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience | Blood Advances | 2022 | 88 |
| 7 | Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry | British Journal of Haematology | 2022 | 85 |
| 8 | Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report | Blood | 2017 | 73 |
| 9 | Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy | Blood | 2017 | 68 |
| 10 | Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia | Blood | 2020 | 62 |
| 11 | Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association | Haematologica | 2017 | 61 |
| 12 | Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties | Clinical Cancer Research | 2013 | 50 |
| 13 | A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features | Clinical Cancer Research | 2020 | 48 |
| 14 | Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma | Blood Advances | 2020 | 48 |
| 15 | An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s Syndrome | Leukemia and Lymphoma | 2016 | 47 |
| 16 | Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study | British Journal of Haematology | 2021 | 43 |
| 17 | Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier | Journal of Molecular Diagnostics | 2017 | 39 |
| 18 | Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older | Journal of Clinical Oncology | 2021 | 39 |
| 19 | Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study | Journal of Hematology and Oncology | 2016 | 35 |
| 20 | Granulomatous lesions in bone marrow: Clinicopathologic findings and significance in a study of 48 cases | European Journal of Internal Medicine | 2013 | 34 |
| 21 | Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? | Journal of Hematology and Oncology | 2013 | 31 |
| 22 | High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia | World Journal of Stem Cells | 2017 | 31 |
| 23 | Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA | Annals of Oncology | 2013 | 30 |
| 24 | Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel | Blood | 2018 | 28 |
| 25 | Rituximab–cyclophosphamide–dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia | Leukemia and Lymphoma | 2011 | 26 |
| 26 | Body mass index and other anthropometric parameters in patients with diffuse large B-cell lymphoma: physiopathological significance and predictive value in the immunochemotherapy era | Leukemia and Lymphoma | 2015 | 26 |
| 27 | Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients | PLoS ONE | 2017 | 25 |
| 28 | Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? | Hematological Oncology | 2018 | 25 |
| 29 | Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma | Haematologica | 2015 | 24 |
| 30 | Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis | Human Pathology | 2014 | 23 |
| 31 | Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10 | Expert Review of Clinical Pharmacology | 2017 | 22 |
| 32 | Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma | Blood Cancer Journal | 2020 | 22 |
| 33 | EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma | Future Oncology | 2021 | 20 |
| 34 | FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2018 | 19 |
| 35 | Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study | Blood Advances | 2021 | 19 |
| 36 | Suggestive evidence of a role of HLA-DRB4 mismatches in the outcome of allogeneic hematopoietic stem cell transplantation with HLA-10/10-matched unrelated donors: a French–Swiss retrospective study | Bone Marrow Transplantation | 2015 | 18 |
| 37 | Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia | Clinical Lymphoma, Myeloma and Leukemia | 2015 | 18 |
| 38 | Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients | Blood | 2021 | 18 |
| 39 | TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE | Mediterranean Journal of Hematology and Infectious Diseases | 2016 | 17 |
| 40 | Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients | Leukemia | 2018 | 16 |
| 41 | Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe). | Blood | 2012 | 16 |
| 42 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma | Lupus Science and Medicine | 2017 | 15 |
| 43 | Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience | Cancers | 2019 | 14 |
| 44 | Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding | Oncotarget | 2017 | 14 |
| 45 | Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study | Oncotarget | 2016 | 13 |
| 46 | Accurate quantification of fourteen normal bone marrow cell subsets in infants to the elderly by flow cytometry | Cytometry Part B - Clinical Cytometry | 2018 | 13 |
| 47 | Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study | Bone Marrow Transplantation | 2021 | 13 |
| 48 | Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma | Leukemia | 2021 | 13 |
| 49 | Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience | Leukemia and Lymphoma | 2017 | 12 |
| 50 | SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma | Annals of Hematology | 2018 | 12 |
